Shanghai Shen Lian Biomedical Corporation manufactures and sells synthetic peptide vaccines for the prevention of porcine O-and A-type foot-and-mouth disease in China. More Details
Solid track record with excellent balance sheet.
Share Price & News
How has Shanghai Shen Lian Biomedical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 688098 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 688098's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 688098 underperformed the CN Pharmaceuticals industry which returned 14.4% over the past year.
Return vs Market: 688098 underperformed the CN Market which returned 27.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Shanghai Shen Lian Biomedical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Shanghai Shen Lian Biomedical undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 688098 (CN¥13.37) is trading above our estimate of fair value (CN¥1.6)
Significantly Below Fair Value: 688098 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 688098 is poor value based on its PE Ratio (43.1x) compared to the CN Pharmaceuticals industry average (30.9x).
PE vs Market: 688098 is poor value based on its PE Ratio (43.1x) compared to the CN market (34.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 688098's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 688098 is overvalued based on its PB Ratio (3.9x) compared to the CN Pharmaceuticals industry average (2.8x).
How is Shanghai Shen Lian Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Shen Lian Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Shanghai Shen Lian Biomedical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 688098 has high quality earnings.
Growing Profit Margin: 688098's current net profit margins (37.6%) are higher than last year (30.8%).
Past Earnings Growth Analysis
Earnings Trend: 688098's earnings have grown by 8.6% per year over the past 5 years.
Accelerating Growth: 688098's earnings growth over the past year (62.6%) exceeds its 5-year average (8.6% per year).
Earnings vs Industry: 688098 earnings growth over the past year (62.6%) exceeded the Pharmaceuticals industry 10.9%.
Return on Equity
High ROE: 688098's Return on Equity (9.1%) is considered low.
How is Shanghai Shen Lian Biomedical's financial position?
Financial Position Analysis
Short Term Liabilities: 688098's short term assets (CN¥875.6M) exceed its short term liabilities (CN¥153.2M).
Long Term Liabilities: 688098's short term assets (CN¥875.6M) exceed its long term liabilities (CN¥5.0M).
Debt to Equity History and Analysis
Debt Level: 688098's debt to equity ratio (1.6%) is considered satisfactory.
Reducing Debt: 688098's debt to equity ratio has reduced from 14.1% to 1.6% over the past 5 years.
Debt Coverage: 688098's debt is well covered by operating cash flow (446.1%).
Interest Coverage: Insufficient data to determine if 688098's interest payments on its debt are well covered by EBIT.
What is Shanghai Shen Lian Biomedical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 688098's dividend (0.6%) is higher than the bottom 25% of dividend payers in the CN market (0.42%).
High Dividend: 688098's dividend (0.6%) is low compared to the top 25% of dividend payers in the CN market (1.79%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether 688098's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if 688098's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (25.8%), 688098's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Shanghai Shen Lian Biomedical has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Shanghai Shen Lian Biomedical Corporation's company bio, employee growth, exchange listings and data sources
- Name: Shanghai Shen Lian Biomedical Corporation
- Ticker: 688098
- Exchange: SHSE
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥5.478b
- Shares outstanding: 409.70m
- Website: https://www.shenlianbiotech.com.cn
Number of Employees
- Shanghai Shen Lian Biomedical Corporation
- No. 48 Jiangchuan East Road
- Zizhu Science Park
Shanghai Shen Lian Biomedical Corporation manufactures and sells synthetic peptide vaccines for the prevention of porcine O-and A-type foot-and-mouth disease in China. The company has a strategic partnersh...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 09:01|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.